• Dinaciclib Selectively Targets VHL-Deficient CC-RCC

  2026-08-29

  Nelson and colleagues identified a synthetic-lethal relationship between Dinaciclib treatment and loss of the von Hippel–Lindau tumor suppressor in clear cell renal cell carcinoma. Their combination of cell-based assays, mechanistic signaling analysis, and an orthotopic patient-derived xenograft model supports selective targeting of both bulk tumor cells and CD105-positive cancer stem-like cells.

• RITA (NSC 652287): p53 Research Guide

  2026-08-28

  RITA (NSC 652287) is an MDM2-p53 interaction inhibitor for cancer biology research. Product-reported nanomolar activity in renal carcinoma cells and tumor xenograft regression support its use as a research tool, while assay design must distinguish growth inhibition from direct cell killing.

• Vorinostat for HDAC and Apoptosis Assays

  2026-08-28

  Build reproducible cancer-cell workflows with Vorinostat, a soluble-in-DMSO HDAC inhibitor that links histone acetylation to mitochondrial apoptosis. Use dose–response profiling, chromatin readouts, and orthogonal cell-death assays to distinguish transcriptional effects from the execution of apoptosis.

• Spatial Kidney Assembloids for Disease Modeling

  2026-08-27

  Huang et al. developed spatially patterned mouse and human kidney progenitor assembloids that better reproduce nephron–collecting duct organization, maturation, and selected kidney functions than conventional organoids. Their genome-edited PKD2-deficient human assembloids also modeled cystic disease and revealed interactions among cyst epithelium, stroma, and macrophages, providing a more physiologically relevant platform for kidney disease research.

• HyperScribe T7 High Yield RNA Synthesis Kit Plus

  2026-08-27

  The HyperScribe T7 High Yield RNA Synthesis Kit Plus is a T7 RNA polymerase in vitro transcription kit for producing research-scale RNA transcripts, including modified, labeled, and biotinylated designs. Its product specifications report up to 180 μg of RNA from a 20 μL reaction containing 1 μg of control template.

• Mdivi-1 Workflows for DRP1 and Apoptosis

  2026-08-26

  Mdivi-1 provides a cell-permeable way to test how DRP1-dependent mitochondrial fission contributes to fragmentation, mitochondrial outer membrane permeabilization, and apoptosis. This practical guide connects assay design with ECM-driven mitochondrial remodeling and outlines controls for cell, retina, and mechanistic studies.

• VX-765: From Caspase-1 Mechanism to Translation

  2026-08-26

  A mechanistic and strategic guide to using VX-765 and VRT-043198 for cytokine processing, pyroptosis, cross-caspase selectivity, and translational inflammation research.

• 2-APB and the Next Era of Calcium Signaling

  2026-08-25

  A translational perspective on how 2-APB (2-aminoethoxydiphenyl borate) can separate IP3R-mediated calcium release, TRPC activity, and store-operated calcium entry from the upstream Gαq–PLCβ3 axis highlighted by recent cardiovascular research.

• Prenatal Dexamethasone and Mkp-1 Epigenetics

  2026-08-25

  This study identifies an epigenetic mechanism linking prenatal dexamethasone exposure to reduced osteoprogenitor proliferation and impaired bone development in mouse offspring. Its results connect loss of H3K9me2 and H3K27me3 at the Mkp-1 locus with increased MKP-1 expression, suppressed MAPK signaling, and a persistent skeletal phenotype.

• Nose-to-Brain Rotigotine Nanoparticles in PD

  2026-08-24

  Bhattamisra and colleagues developed rotigotine-loaded chitosan nanoparticles to address solubility, bioavailability, and brain-delivery barriers in Parkinson’s disease models. In SH-SY5Y cells and haloperidol-treated rats, the formulation improved markers of neuronal integrity, antioxidant activity, and motor performance, supporting nose-to-brain delivery as a formulation strategy rather than establishing clinical efficacy.

• Imipramine: From Lipidomics to Assay Design

  2026-08-24

  Imipramine is a tricyclic antidepressant with applications spanning autophagy, apoptosis, neuroscience, and cancer biology. This article develops a lipidomics-informed framework for interpreting Imipramine experiments without mistaking correlation for mechanism.

• NSC 87877 Workflows for Shp2 Signaling

  2026-08-23

  NSC 87877 is a practical Shp2 inhibitor for connecting phosphatase activity with Erk signaling, microglial NLRP3 responses, and cell viability. This guide translates the tFUS–Nespas/miR-383-3p/SHP2 study into assay-ready workflows while separating evidence-backed findings from recommended optimization steps.

• Fad2 and Acsl4 Link Lipid Metabolism to Rice Blast

  2026-08-22

  The 2024 study identifies Magnaporthe oryzae Fad2 and Acsl4 as contributors to polyunsaturated fatty acid-containing phospholipid production, ferroptotic conidial death, and pathogenic development. Genetic disruption, targeted lipidomics, chemical rescue, and protein-interaction analysis connect lipid peroxidation with appressorium-mediated infection while highlighting targets for future rice blast control.

• GS-441524 Workflows for Prodrug Conversion Studies

  2026-08-22

  Build more informative antiviral assays by measuring GS-441524 alongside its prodrug precursor across gastric, blood, microsomal, and pharmacokinetic matrices. This workflow turns a soluble-stock challenge into a practical LC–MS/MS strategy for tracing conversion, improving recovery, and interpreting exposure.

• (-)-Arctigenin: MEK1 Inhibitor Research Guide

  2026-08-21

  (-)-Arctigenin is a research small molecule described as a MEK1 inhibitor and iNOS expression inhibitor. The product dossier reports nanomolar activity in biochemical or cell-based contexts, while breast cancer evidence supports NF-κB pathway relevance but does not directly establish arctigenin efficacy.

8041 records 1/537 page Next 12345 下5页 Last page